Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyaluronidase added to ropivacaine for fascia iliaca compartment block
ACTRN12612000401853Phase 4Not yet recruiting
- Sponsor
- Dr Andrew Kenneth Lansdown
- Start
- Oct 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of hyaluronidase and ropivacaine in postoperative pain (2 arms), sponsored by Dr Andrew Kenneth Lansdown. Primary endpoint: Success of fascia iliaca compartment block. Planned start Oct 2010; status: not yet recruiting.
02
Drugs
hyaluronidaseropivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on ACTRN12612000401853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000401853.